Every 8-K that DAXOR CORP (DXR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DXR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DXR filings page.
Daxor Corporation held its Annual Meeting on June 23, 2026, where shareholders elected six directors for terms ending at the 2027 annual meeting. Henry D. Cremisi, Edward Feuer, Joy Goudie, Michael Feldschuh, Jonathan Feldschuh, and Caleb DesRosiers each received strong majority support, with individual "for" votes ranging from about 4.1 million to 4.4 million shares.
Shareholders also approved the ratification of Bush & Associates, CPA as Daxor’s independent registered public accounting firm, with 4,423,295 votes for, 19,839 against, and 401 abstentions. The filing reiterates that Daxor, listed on Nasdaq as DXR, is a medical instrumentation and biotechnology company focused on its FDA-cleared BVA-100 blood volume analyzer.
Daxor Corporation entered into a definitive securities purchase agreement on January 23, 2026, to raise capital through a registered direct offering. The company issued and sold an aggregate of 765,958 registered shares of common stock at $11.75 per share, resulting in approximately $8,142,006 in net proceeds after placement agent fees and expenses. The closing occurred on January 26, 2026.
The common shares were issued under Daxor’s shelf registration statement on Form N-2 (File No. 333-281622), which was declared effective by the SEC on January 20, 2026. Lake Street Capital Markets, LLC acted as placement agent under a placement agency agreement executed the same day as the securities purchase agreement. The company also filed a legal opinion from Foley & Lardner LLP regarding the validity of the common stock.
Daxor Corporation filed a current report to share its latest investor presentation with the market. The company used an 8-K under the "Other Events" section to formally furnish this material.
The filing states that the current investor presentation is attached as Exhibit 99.1, making it part of the public record. Daxor’s common stock, with a par value of $0.01 per share, trades on Nasdaq under the symbol DXR.